Andreas Mackensen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2723011/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reduced cytotoxicity by mutation of lysine 590 of <i>Pseudomonas</i> exotoxin can be restored in an optimized, lysine-free immunotoxin. Immunotherapy Advances, 2022, 2, .	3.0	0
2	Bone marrow stroma cells promote induction of a chemoresistant and prognostic unfavorable S100A8/A9high AML cell subset. Blood Advances, 2022, 6, 5685-5697.	5.2	11
3	Midkine Promotes Metastasis and Therapeutic Resistance via mTOR/RPS6 in Uveal Melanoma. Molecular Cancer Research, 2022, 20, 1320-1336.	3.4	2
4	The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. , 2022, 10, e004475.		50
5	CLL-Derived Extracellular Vesicles Impair T-Cell Activation and Foster T-Cell Exhaustion via Multiple Immunological Checkpoints. Cells, 2022, 11, 2176.	4.1	8
6	The metabolic profile of reconstituting T-cells, NK-cells, and monocytes following autologous stem cell transplantation and its impact on outcome. Scientific Reports, 2022, 12, .	3.3	2
7	Impact of Nrf2 expression in reconstituting T-cells of allogeneic hematopoietic stem cell transplanted patients. Leukemia, 2021, 35, 910-915.	7.2	6
8	Hydrogen-Peroxide Synthesis and LDL-Uptake Controls Immunosuppressive Properties in Monocyte-Derived Dendritic Cells. Cancers, 2021, 13, 461.	3.7	4
9	Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia, 2021, 35, 2517-2525.	7.2	40
10	The IKZF1–IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages. Cancer Immunology Research, 2021, 9, 265-278.	3.4	26
11	Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy. Cancers, 2021, 13, 1481.	3.7	20
12	Upregulation of CCR4 in activated CD8 ⁺ T cells indicates enhanced lung homing in patients with severe acute SARSâ€CoVâ€2 infection. European Journal of Immunology, 2021, 51, 1436-1448.	2.9	22
13	Targeting of canonical WNT signaling ameliorates experimental sclerodermatous chronic graft-versus-host disease. Blood, 2021, 137, 2403-2416.	1.4	11
14	CD137 (4-1BB) stimulation leads to metabolic and functional reprogramming of human monocytes/macrophages enhancing their tumoricidal activity. Leukemia, 2021, 35, 3482-3496.	7.2	22
15	CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood, 2021, 138, 2499-2513.	1.4	160
16	Human CD4+ T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential. Clinical and Experimental Immunology, 2021, 205, 363-378.	2.6	34
17	Expression of disialoganglioside GD2 and prognosis in breast cancer subtypes. Senologie - Zeitschrift FA¼r Mammadiagnostik Und -therapie, 2021, 18, .	0.0	0
18	Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. , 2021, 9, e002605.		7

#	Article	IF	CITATIONS
19	The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer Agents. Journal of Clinical Oncology, 2021, 39, 1983-1994.	1.6	37
20	Successful treatment of COVIDâ€19 infection with convalescent plasma in Bâ€cellâ€depleted patients may promote cellular immunity. European Journal of Immunology, 2021, 51, 2478-2484.	2.9	8
21	Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments. International Journal of Molecular Sciences, 2021, 22, 10433.	4.1	3
22	A distinct CD38+CD45RA+ population of CD4+, CD8+, and double-negative T cells is controlled by FAS. Journal of Experimental Medicine, 2021, 218, .	8.5	25
23	Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. Cancers, 2021, 13, 5577.	3.7	5
24	Protein kinase C-β-dependent changes in the glucose metabolism of bone marrow stromal cells of chronic lymphocytic leukemia. Stem Cells, 2021, 39, 819-830.	3.2	5
25	The CAR-Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL. Blood, 2021, 138, 3852-3852.	1.4	1
26	An Easily Expandable Multi-Drug LC-MS Assay for the Simultaneous Quantification of 57 Oral Antitumor Drugs in Human Plasma. Cancers, 2021, 13, 6329.	3.7	9
27	The Oncometabolite 5′-Deoxy-5′-Methylthioadenosine Blocks Multiple Signaling Pathways of NK Cell Activation. Frontiers in Immunology, 2020, 11, 2128.	4.8	6
28	P03.20â€A murine, myc-driven lymphoma model expressing human CD22 enables testing of targeted therapies and their effects on tumor immune microenvironment. , 2020, , .		0
29	P09.14â€Blocking counterregulation of unfolded protein response by targeted protein synthesis inhibition produces highly synergistic cell death in several cancer entities. , 2020, , .		Ο
30	Linking Immunoevasion and Metabolic Reprogramming in B-Cell–Derived Lymphomas. Frontiers in Oncology, 2020, 10, 594782.	2.8	13
31	Discovery and Differential Processing of HLA Class II-Restricted Minor Histocompatibility Antigen LB-PIP4K2A-1S and Its Allelic Variant by Asparagine Endopeptidase. Frontiers in Immunology, 2020, 11, 381.	4.8	7
32	Palmitoylated Proteins on AML-Derived Extracellular Vesicles Promote Myeloid-Derived Suppressor Cell Differentiation via TLR2/Akt/mTOR Signaling. Cancer Research, 2020, 80, 3663-3676.	0.9	30
33	Measuring the cellular memory B cell response after vaccination in patients after allogeneic stem cell transplantation. Annals of Hematology, 2020, 99, 1895-1906.	1.8	6
34	N-glycosylation controls inflammatory licensing-triggered PD-L1 upregulation in human mesenchymal stromal cells. Stem Cells, 2020, 38, 986-993.	3.2	10
35	Selective PRMT5 Inhibitors Suppress Human CD8+ T Cells by Upregulation of p53 and Impairment of the AKT Pathway Similar to the Tumor Metabolite MTA. Molecular Cancer Therapeutics, 2020, 19, 409-419.	4.1	29
36	Abstract 1021: A novel interaction between hydrogen peroxide metabolism and LDL-uptake controls immunergulatory properties in human dendritic cells - Potential implications for tumor immune escape. , 2020, , .		0

#	Article	IF	CITATIONS
37	Inflammation-induced glycolytic switch controls suppressivity of mesenchymal stem cells via STAT1 glycosylation. Leukemia, 2019, 33, 1783-1796.	7.2	54
38	Human Double-Negative Regulatory T-Cells Induce a Metabolic and Functional Switch in Effector T-Cells by Suppressing mTOR Activity. Frontiers in Immunology, 2019, 10, 883.	4.8	32
39	A novel immunoregulatory function of beta-2-microglobulin as a promoter of myeloid derived suppressor cell induction. Leukemia, 2019, 33, 1282-1287.	7.2	1
40	Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide. Blood, 2019, 134, 4064-4064.	1.4	6
41	Combination of lenalidomide and vitamin D enhances MOR202-mediated cytotoxicity of macrophages: It takes three to tango. Oncotarget, 2019, 10, 10-12.	1.8	5
42	Characterization of CD4+ T cells primed and boosted by MHCII primary uveal melanoma cell-based vaccines. Oncotarget, 2019, 10, 1812-1828.	1.8	7
43	Abstract P2-09-04: Identification of a neoantigen targeted by tumor-infiltrating lymphocytes in a patient with Her2+ breast cancer. , 2019, , .		0
44	Chaperone protein HSC70 regulates intercellular transfer of Y chromosome antigen DBY. Journal of Clinical Investigation, 2019, 129, 2952-2963.	8.2	0
45	Microenvironmental Triggers Induce a Chemoresistant, Differentiated Subset of S100A8/A9high AML Cells Via the Jak/STAT3 Signaling Axis. Blood, 2019, 134, 2714-2714.	1.4	0
46	β2-m - a Trigger for NLRP3 Inflammasome Activation within Macrophages Promoting Multiple Myeloma Cell Proliferation. Blood, 2019, 134, 2314-2314.	1.4	0
47	TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes. Breast Care, 2018, 13, 8-14.	1.4	32
48	D-2-hydroxyglutarate interferes with HIF-1α stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization. Oncolmmunology, 2018, 7, e1445454.	4.6	97
49	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature Medicine, 2018, 24, 282-291.	30.7	216
50	Dose adjustment of cisplatin, etoposide, and ifosfamide according to kidney function: a retrospective analysis and implications for medication safety. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 219-229.	3.0	3
51	Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway. Leukemia, 2018, 32, 2445-2458.	7.2	36
52	Visualizing Single-Cell Secretion Dynamics with Single-Protein Sensitivity. Nano Letters, 2018, 18, 513-519.	9.1	50
53	Label-Free Imaging of Single Proteins Secreted from Living Cells via iSCAT Microscopy. Journal of Visualized Experiments, 2018, , .	0.3	15
54	CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells. , 2018, 6, 116.		61

4

#	Article	IF	CITATIONS
55	Whole-Body Electromyostimulation Combined With Individualized Nutritional Support Improves Body Composition in Patients With Hematological Malignancies – A Pilot Study. Frontiers in Physiology, 2018, 9, 1808.	2.8	22
56	Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma. Blood, 2018, 132, 2744-2753.	1.4	27
57	Impact of collection programs for the generation of monocyte apheresis products on product quality and composition as starting material for the generation of cellular therapeutics. Transfusion, 2018, 58, 2175-2183.	1.6	2
58	Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells. Oncolmmunology, 2018, 7, e1472195.	4.6	21
59	Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts. Journal of Translational Medicine, 2018, 16, 124.	4.4	16
60	Depletion of donor-specific anti-HLA A2 alloantibodies in a hematopoietic cell transplant recipient using directed mismatched platelet transfusions. Bone Marrow Transplantation, 2018, 53, 791-794.	2.4	3
61	BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease. Journal of Clinical Investigation, 2018, 128, 916-930.	8.2	34
62	Human Double-Negative Regulatory T Cells Modulate Effector Functions of Conventional T Cells By Selectively Blocking mTOR Signaling. Blood, 2018, 132, 2410-2410.	1.4	2
63	IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner. Oncotarget, 2018, 9, 13125-13138.	1.8	58
64	Vaccination after Allogenic Stem Cell Transplantation: Diminished Memory B Cell Response and High Number of Spontaneously IgG Secreting Plasmablasts. Blood, 2018, 132, 4567-4567.	1.4	0
65	Role of N6-Methyladenosine (m6A) RNA Modification in Multiple Myeloma. Blood, 2018, 132, 5601-5601.	1.4	1
66	Characterizing the Immunogenicity of DM-Sensitive and DM-Resistant Antigens. Blood, 2018, 132, 3310-3310.	1.4	0
67	Stroma Cells Promote a S100A8/A9high-Subset of AML Blasts with Distinct Metabolic Features in a Jak/STAT3-Dependent Manner. Blood, 2018, 132, 2807-2807.	1.4	Ο
68	Effect of Proinflammatory and Homeostatic Cytokines on the Functionality of Human Double-Negative Regulatory T Cells. Blood, 2018, 132, 3726-3726.	1.4	0
69	Myc-Driven, Primary Mouse Lymphoma Expressing Human CD22 Are Highly Infiltrated By Syngeneic Immune Cells and Provide a Unique Model to Test CD22-Targeted Therapies. Blood, 2018, 132, 1673-1673.	1.4	Ο
70	TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients – First Results on the Influence of Tumor-Infiltrating Lymphocytes. , 2018, 78, .		0
71	Systematic comparison of donor chimerism in peripheral blood and bone marrow after hematopoietic stem cell transplantation. Blood Cancer Journal, 2017, 7, e566-e566.	6.2	14
72	CLL-cell-mediated MDSC induction by exosomal miR-155 transfer is disrupted by vitamin D. Leukemia, 2017, 31, 985-988.	7.2	62

#	Article	IF	CITATIONS
73	Sunitinib does not impair natural killer cell function in patients with renal cell carcinoma. Oncology Letters, 2017, 14, 1089-1096.	1.8	2
74	Impaired Transmigration of Myeloid-Derived Suppressor Cells across Human Sinusoidal Endothelium Is Associated with Decreased Expression of CD13. Journal of Immunology, 2017, 199, 1672-1681.	0.8	10
75	The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia. Leukemia, 2017, 31, 470-478.	7.2	78
76	GMP-production of purified human B lymphocytes for the adoptive transfer in patients after allogeneic hematopoietic stem cell transplantation. Journal of Translational Medicine, 2017, 15, 228.	4.4	13
77	The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial. Blood, 2017, 130, 721-721.	1.4	20
78	Abstract CT028: Adoptive transfer of CMV- and EBV- specific peptide-stimulated T cells after allogeneic stem cell transplantation: A Phase I/IIa clinical trial. , 2017, , .		0
79	Abstract 3971: MTA-mediated inhibition of human T cells: Mechanism and MTAP overexpression as putative overcoming strategy. Cancer Research, 2017, 77, 3971-3971.	0.9	1
80	Mesenchymal Stromal Cells Disrupt mTOR-Signaling and Aerobic Glycolysis During T-Cell Activation. Stem Cells, 2016, 34, 516-521.	3.2	39
81	Human lymphoid organ dendritic cell identity is predominantly dictated by ontogeny, not tissue microenvironment. Science Immunology, 2016, 1, .	11.9	145
82	Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2016, 34, 2484-2492.	1.6	106
83	Specific phenotype and function of CD56-expressing innate immune cell subsets in human thymus. Journal of Leukocyte Biology, 2016, 100, 1297-1310.	3.3	3
84	LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metabolism, 2016, 24, 657-671.	16.2	1,126
85	Hyperactive mTOR pathway promotes lymphoproliferation and abnormal differentiation in autoimmune lymphoproliferative syndrome. Blood, 2016, 128, 227-238.	1.4	77
86	Suppressive effects of tumor cell-derived 5′-deoxy-5′-methylthioadenosine on human T cells. Oncolmmunology, 2016, 5, e1184802.	4.6	48
87	The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia. Oncolmmunology, 2016, 5, e1101206.	4.6	31
88	Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. Journal of Clinical Oncology, 2016, 34, 1104-1111.	1.6	359
89	CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis. Leukemia, 2016, 30, 1788-1792.	7.2	31
90	Adoptive Transfer of CMV- and EBV- Specific Peptide-Stimulated T Cells after Allogeneic Stem Cell Transplantation: First Results of a Phase I/IIa Clinical Trial [Multivir-01]. Blood, 2016, 128, 2179-2179.	1.4	1

#	Article	IF	CITATIONS
91	Adoptive Transfer of Purified Donor-B-Lymphocytes after Allogeneic Stem Cell Transplantation: Results from a Phase I/IIa Clinical Trial. Blood, 2016, 128, 502-502.	1.4	11
92	Abstract 5118: 5'-deoxy-5'-methylthioadenosine (MTA) impairs human T-cell functions and constitutes a novel immuno-suppressing tumor metabolite. , 2016, , .		0
93	Human Double-Negative Regulatory T Cells Selectively Suppress mTOR Signaling and Metabolic Reprogramming of Conventional T Cells. Blood, 2016, 128, 3694-3694.	1.4	0
94	Indirect Presentation of Y-Chromosome Antigen Dby Is Regulated By Hsc70 and Mediated through CD63 Positive Exosomes. Blood, 2016, 128, 3712-3712.	1.4	0
95	Vitamin D Blocks CLL Cell-Mediated MDSC Induction. Blood, 2016, 128, 4355-4355.	1.4	0
96	the IKZF1-IRF4 Axis Regulates Macrophage Polarization and Macrophage-Mediated Anti-Tumor Immunity. Blood, 2016, 128, 2514-2514.	1.4	5
97	NK Cell Subgroups, Phenotype, and Functions After Autologous Stem Cell Transplantation. Frontiers in Immunology, 2015, 6, 583.	4.8	19
98	Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects. Oncolmmunology, 2015, 4, e981483.	4.6	38
99	CD47 Enhances <i>In Vivo</i> Functionality of Artificial Antigen-Presenting Cells. Clinical Cancer Research, 2015, 21, 2075-2083.	7.0	23
100	Contact-Dependent Depletion of Hydrogen Peroxide by Catalase Is a Novel Mechanism of Myeloid-Derived Suppressor Cell Induction Operating in Human Hepatic Stellate Cells. Journal of Immunology, 2015, 194, 2578-2586.	0.8	18
101	Monitoring of Hematopoietic Chimerism by Real-Time Quantitative PCR of Micro Insertions/Deletions in Samples with Low DNA Quantities. Transfusion Medicine and Hemotherapy, 2015, 42, 38-45.	1.6	23
102	Su1699 Development and Initial Validation of a Diagnosis and Grading Score of Acute Gastrointestinal Graft-Versus-Host Disease by Probe-Based Confocal LASER Endomicroscopy (pCLE). Gastrointestinal Endoscopy, 2015, 81, AB383.	1.0	0
103	Vitamin D–dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma. Science Translational Medicine, 2015, 7, 282ra47.	12.4	72
104	Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncology, The, 2015, 16, 1691-1699.	10.7	347
105	IL-7 Abrogates the Immunosuppressive Function of Human Double-Negative T Cells by Activating Akt/mTOR Signaling. Journal of Immunology, 2015, 195, 3139-3148.	0.8	16
106	Lenalidomide Enhances MOR202 Dependent Macrophage-Mediated Effector Functions Via the Vitamin D Pathway. Blood, 2015, 126, 2203-2203.	1.4	3
107	A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells. MAbs, 2014, 6, 286-296.	5.2	14
108	Abnormally differentiated CD4+ or CD8+ T cells with phenotypic and genetic features of double negative T cells in human Fas deficiency. Blood, 2014, 124, 851-860.	1.4	54

#	Article	IF	CITATIONS
109	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncology, The, 2014, 15, 297-304.	10.7	55
110	Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood, 2014, 123, 2663-2672.	1.4	164
111	Nilotinib combined with interleukin-2 mediates antitumor and immunological effects in a B16 melanoma model. Oncology Reports, 2014, 31, 2015-2020.	2.6	9
112	CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood, 2014, 124, 750-760.	1.4	206
113	Re-Educating Myeloma Associated Macrophages with Lenalidomide. Blood, 2014, 124, 2034-2034.	1.4	14
114	Metabolic Reprogramming of Acute Myeloid Leukemia Blasts By Bone Marrow Stroma Cells. Blood, 2014, 124, 1585-1585.	1.4	0
115	Vitamin D-Dependent Induction of Cathelicidin in Human Macrophages Results in Cytotoxicity Against High Grade B-Cell Lymphoma. Blood, 2014, 124, 4108-4108.	1.4	1
116	Interleukin-7 Represses the Immunoregulatory Function of Human TCRαβ+ CD4- CD8- Double-Negative (DN) T Cells By Activating Akt/mTOR Signaling. Blood, 2014, 124, 4133-4133.	1.4	0
117	T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia, 2013, 27, 1107-1115.	7.2	108
118	A recombinant triplebody with specificity for CD19 and HLA-DR mediates †preferential binding to antigen double-positive cells by dual-targeting. MAbs, 2012, 4, 45-56.	5.2	24
119	Tumor metabolism as modulator of immune response and tumor progression. Seminars in Cancer Biology, 2012, 22, 335-341.	9.6	89
120	Influence of NK cell magnetic bead isolation methods on phenotype and function of murine NK cells. Journal of Immunological Methods, 2012, 378, 1-10.	1.4	21
121	NK Cell Subsets Isolated From Human Thymus Differ From Peripheral Blood NK Cells in Their Cytotoxic and Cytokine Secreting Capability. Blood, 2012, 120, 1053-1053.	1.4	0
122	Suppression of T-cell responses by tumor metabolites. Cancer Immunology, Immunotherapy, 2011, 60, 425-431.	4.2	76
123	Characterization of the immunoregulatory function of human TCRâ€Î±Î² ⁺ CD4 ^{â²} CD8 ^{â²²} doubleâ€negative T cells. European Journal of Immunology, 2011, 41, 739-748.	2.9	95
124	Warburg phenotype in renal cell carcinoma: High expression of glucoseâ€transporter 1 (GLUTâ€1) correlates with low CD8 ⁺ Tâ€cell infiltration in the tumor. International Journal of Cancer, 2011, 128, 2085-2095.	5.1	122
125	Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: A case report. Leukemia Research, 2010, 34, e270-e272.	0.8	29
126	Novel conjugates of singleâ€chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. British Journal of Haematology, 2010, 148, 879-889.	2.5	63

#	Article	IF	CITATIONS
127	A recombinant trispecific singleâ€chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. British Journal of Haematology, 2010, 150, 574-586.	2.5	115
128	In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunology, Immunotherapy, 2009, 58, 209-220.	4.2	43
129	Characterization of MHC class-I restricted TCRαβ+ CD4â^' CD8â^' double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination. Cancer Immunology, Immunotherapy, 2009, 58, 709-718.	4.2	37
130	Inhibitory effect of tumor cell–derived lactic acid on human T cells. Blood, 2007, 109, 3812-3819.	1.4	1,361
131	Phase I Study of Adoptive T-Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2006, 24, 5060-5069.	1.6	290
132	Expression of Proteinase Inhibitor-9 in Primary AML Blasts and Its Regulation by Interferon-Î ³ : A Potential Immune Escape Mechanism after Allogeneic Stem Cell Transplantation Blood, 2006, 108, 3687-3687.	1.4	0
133	Antigen Recognition Induces Phosphatidylserine Exposure on the Cell Surface of Human CD8+ T Cells Blood, 2006, 108, 1718-1718.	1.4	0
134	Isolation and characterization of human antigen-specific TCRαβ+ CD4-CD8- double-negative regulatory T cells. Blood, 2005, 105, 2828-2835.	1.4	222
135	Isolation and Characterization of Human Antigen-Specific TCRαβ+ CD4â^'CD8â^' Double Negative Regulatory T Cells Blood, 2005, 106, 3306-3306.	1.4	1
136	Adoptive T Cell Therapy Using Antigen-Specific CD8+ T Cells for the Treatment of Patients with Cancer: A Phase I Clinical Study Blood, 2005, 106, 2393-2393.	1.4	0
137	Is Survivin a Possible Target Antigen for Cellular Immunotherapy in Multiple Myeloma? Blood, 2005, 106, 5145-5145.	1.4	0
138	Tumor-Derived Lactic Acid Modulates Dendritic Cell Activation and Differentiation Blood, 2004, 104, 4246-4246.	1.4	1
139	Inhibitory Effects of Lactic Acid on Human Antigen-Specific CD8+ T-Cells Blood, 2004, 104, 3844-3844.	1.4	0
140	Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells. Nature Medicine, 2003, 9, 619-625.	30.7	291
141	Survival and Tumor Localization of Adoptively Transferred Melan-A-Specific T Cells in Melanoma Patients. Journal of Immunology, 2003, 170, 2161-2169.	0.8	165
142	Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. International Journal of Cancer, 2001, 91, 749-756.	5.1	73
143	Induction and large-scale expansion of CD8+ tumor specific cytotoxic T lymphocytes from peripheral blood lymphocytes by in vitro stimulation with CD80-transfected autologous melanoma cells. European Cytokine Network, 1999, 10, 329-36.	2.0	9
144	Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Research, 1993, 53, 3569-73.	0.9	91